OLMESARTAN MEDOXOMIL

Olmesartan medoxomil is a prodrug ARB offering improved bioavailability for hypertension control. Side effects include hypotension, GI symptoms, and renal function changes.

SKU: dcc1d5f988f7 Category: Tag:

Product Description


Mechanism of Action

OLMESARTAN MEDOXOMIL (ID 26948) shows a complex, multi‑pathway biochemical interaction profile involving modulation of enzyme‑regulated catalytic cycles, receptor‑level signalling networks, intracellular ion dynamics, mitochondrial respiratory control, redox‑balance adaptation, cytoskeletal organisation and transcription‑factor regulatory behaviour. Its physicochemical structure supports direct or indirect interaction with catalytic residues, allosteric pockets, membrane‑spanning receptors, signalling intermediates and structural proteins, enabling influence over second‑messenger pathways (Ca²⁺, cAMP, IP₃, DAG), phosphorylation kinetics, ROS generation and mitochondrial ATP‑synthesis efficiency.

Depending on concentration, exposure duration and biological substrate, OLMESARTAN MEDOXOMIL may shift metabolic routing, alter vesicular transport, influence chromatin accessibility, modify transcriptional clusters, or recalibrate mitochondrial stress‑response thresholds across diverse experimental models.

Benefits and Advantages

Common applications in research environments include:

  • High‑resolution receptor–ligand interaction analysis and molecular docking validation
  • Enzyme‑kinetic dissection and catalytic‑pathway reconstruction
  • Mitochondrial‑performance assays, redox‑stress modelling and ATP‑flux quantification
  • Multi‑omics integration: transcriptomics, metabolomics, proteomics, phosphoproteomics
  • Cytoskeletal‑dynamics studies involving actin, tubulin and membrane‑tension regulation
  • Apoptosis, autophagy, necroptosis, ferroptosis and stress‑response pathway mapping
  • SAR (structure–activity relationship) investigation and molecular‑optimisation workflows
  • Preclinical pharmacodynamic modelling and mechanistic dose‑response assays

Side Effects and Risks

Potential laboratory‑observed risks include:

  • ROS accumulation and oxidative‑stress imbalance
  • Mitochondrial hyperactivation or respiratory‑chain suppression
  • Disruption of Ca²⁺/Na⁺/K⁺ ionic homeostasis and ion‑channel behaviour
  • Unintended receptor cross‑activation or inhibitory interference
  • Cyto‑architectural destabilisation, membrane fragility or impaired trafficking
  • Dose‑dependent cytotoxicity and activation of apoptosis/autophagy signalling
  • Transcriptional and epigenetic instability under prolonged exposure
  • Inflammatory pathway activation (NF‑κB, MAPK, JNK)

Use exclusively under controlled laboratory conditions, following strict biosafety and handling protocols.

Datasheet


Molecular Formula

C29H30N6O6

Molecular Weight

558.6 g/mol

CAS Number

144689-63-4

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Olmesartan medoxomil; 144689-63-4; Benicar; Olmetec; CS-866

IUPAC/Chemical Name

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

InChl Key

UQGKUQLKSCSZGY-UHFFFAOYSA-N

InChl Code

InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)

References

https://pubchem.ncbi.nlm.nih.gov/compound/130881;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download